The malignant lymphomas, including both Hodgkin lymphoma (HL) and non-Hodgkin
lymphoma (NHL), represent a diverse group of diseases that arise from a clonal proliferation …

In 2004, new cases of non-Hodgkin's lymphoma in the United States were estimated at
54,370, representing 4% of all cancers and resulting 4% of all cancer deaths, and new …

Hodgkin lymphoma is a rare B-cell malignant neoplasm affecting approximately 9000 new
patients annually. This disease represents approximately 11% of all lymphomas seen in the …

T HE term “malignant lymphoma” encompasses a spectrum of diseases of which Hodgkin
disease (HD) is a specific clinical-pathologic entity distinct from the remainder of the …

Systematic studies of the patterns of anatomic distribution, pathways of probable spread,
and prognosis of the malignant lymphomas have been greatly aided by the development of …

The purpose of this work was to modernize recommendations for evaluation, staging, and
response assessment of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma …

Approximately 7350 new cases of Hodgkin lymphoma (HL) are diagnosed annually in the
United States. The incidence of HL has a bimodal pattern, with the highest incidence seen in …

This book provides a well-illustrated, comprehensive, and up-to-date account of Hodgkin
lymphoma. Epidemiology, pathogenesis, and the role of the microenvironment are …

Objectives: Outline the distinguishing features of each classical type of Hodgkin lymphoma.
Review the presentation of Hodgkin lymphoma. Explain how appropriate treatment of a case …

The evolution of our understanding of the biology and management of the disease once
called Hodgkin disease, now called Hodgkin lymphoma (HL), has closely paralleled the …